US4879236A
(en)
*
|
1984-05-16 |
1989-11-07 |
The Texas A&M University System |
Method for producing a recombinant baculovirus expression vector
|
JPS619288A
(ja)
*
|
1984-06-21 |
1986-01-16 |
Dai Ichi Seiyaku Co Ltd |
ペプチド類の製法
|
IL80529A0
(en)
*
|
1985-11-14 |
1987-02-27 |
Daiichi Seiyaku Co |
Method of producing peptides
|
JPS63167797A
(ja)
*
|
1985-12-18 |
1988-07-11 |
マイクロジエネシス,インコ−ポレイテイド |
選択された昆虫宿主細胞中で選択されたポリペプチドを製造する方法
|
IL83003A
(en)
|
1986-07-01 |
1995-07-31 |
Genetics Inst |
Osteoinductive factors
|
US6150328A
(en)
|
1986-07-01 |
2000-11-21 |
Genetics Institute, Inc. |
BMP products
|
GR871029B
(en)
|
1986-07-14 |
1987-11-02 |
Genetics Inst |
Novel osteoinductive factors
|
NZ221702A
(en)
*
|
1986-09-08 |
1989-02-24 |
Bishop David H L |
Expression of human hepatitis b antigens in insects and cultured insect cells using recombinant baculoviruses
|
US5071748A
(en)
*
|
1986-09-09 |
1991-12-10 |
Genetics Institute, Inc. |
Mixed baculovirus compositions and uses thereof
|
ZA876696B
(en)
*
|
1986-09-09 |
1988-05-25 |
Genetics Inst |
Method for producing a heterologous protein in insect cells
|
US5041379A
(en)
*
|
1987-03-16 |
1991-08-20 |
American Biogenetic Science, Inc. |
Heliothis expression systems
|
US5024947A
(en)
*
|
1987-07-24 |
1991-06-18 |
Cetus Corporation |
Serum free media for the growth on insect cells and expression of products thereby
|
US5443964A
(en)
*
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
US5578468A
(en)
*
|
1987-08-10 |
1996-11-26 |
Duke University |
Site-specific RNA cleavage
|
GB8810808D0
(en)
*
|
1988-05-06 |
1988-06-08 |
Wellcome Found |
Vectors
|
JP2511494B2
(ja)
*
|
1988-05-12 |
1996-06-26 |
善治 松浦 |
日本脳炎ウイルス表面抗原蛋白質の製造法
|
JPH0221955A
(ja)
*
|
1988-07-07 |
1990-01-24 |
Nippon Steel Corp |
流体噴射ノズル
|
SE8802939D0
(sv)
*
|
1988-08-19 |
1988-08-19 |
Kabigen Ab |
A method for the production and isolation of a fusion protein in eukaryotic cells
|
US5811523A
(en)
|
1988-11-10 |
1998-09-22 |
Trinchieri; Giorgio |
Antibodies to natural killer stimulatory factor
|
AU4647889A
(en)
*
|
1988-11-18 |
1990-06-12 |
Cetus Corporation |
Insect signal peptide mediated secretion of recombinant proteins
|
US5244805A
(en)
*
|
1989-05-17 |
1993-09-14 |
University Of Georgia Research Foundation, Inc. |
Baculovirus expression vectors
|
JP3504263B2
(ja)
|
1991-11-04 |
2004-03-08 |
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー |
組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
|
WO1994026892A1
(en)
|
1993-05-12 |
1994-11-24 |
Genetics Institute, Inc. |
Bmp-11 compositions
|
US6291206B1
(en)
|
1993-09-17 |
2001-09-18 |
Genetics Institute, Inc. |
BMP receptor proteins
|
US6027919A
(en)
|
1993-12-07 |
2000-02-22 |
Genetics Institute, Inc. |
BMP-12 and BMP-13 proteins and DNA encoding them
|
PT733109E
(pt)
|
1993-12-07 |
2006-07-31 |
Genetics Inst Llc |
Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao
|
WO1995017515A1
(en)
*
|
1993-12-23 |
1995-06-29 |
University Technologies International Inc. |
Methods of expressing proteins in insect cells and methods of killing insects
|
US5629167A
(en)
|
1994-04-19 |
1997-05-13 |
Biocine S.P.A. |
Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US6165748A
(en)
|
1997-07-11 |
2000-12-26 |
Genetics Institute, Inc. |
Frazzled nucleotide sequences and expression products
|
ES2319939T3
(es)
|
1997-08-27 |
2009-05-14 |
Novartis Vaccines And Diagnostics, Inc. |
Mimeticos moleculares de epitopos de meningococos b.
|
EP1029052B1
(en)
|
1997-11-06 |
2010-08-04 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisserial antigens
|
ATE446368T1
(de)
|
1998-01-14 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
GB9808932D0
(en)
|
1998-04-27 |
1998-06-24 |
Chiron Spa |
Polyepitope carrier protein
|
JP5102414B2
(ja)
|
1998-05-01 |
2012-12-19 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
髄膜炎菌抗原および組成物
|
ATE386804T1
(de)
|
1998-10-15 |
2008-03-15 |
Novartis Vaccines & Diagnostic |
Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
|
DK1141331T3
(da)
|
1998-12-16 |
2009-01-05 |
Novartis Vaccines & Diagnostic |
Human cyclinafhængig kinase (hPNQALRE)
|
US6727224B1
(en)
|
1999-02-01 |
2004-04-27 |
Genetics Institute, Llc. |
Methods and compositions for healing and repair of articular cartilage
|
ES2522667T3
(es)
|
1999-04-30 |
2014-11-17 |
Novartis Vaccines And Diagnostics S.R.L. |
Antígenos Neisseriales conservados
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
EP1305412A2
(en)
|
1999-10-14 |
2003-05-02 |
Clontech Laboratories Inc. |
Anthozoa derived chromo/fluoroproteins and methods for using the same
|
ATE271886T1
(de)
|
1999-10-15 |
2004-08-15 |
Inst Genetics Llc |
Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
|
CA2863668A1
(en)
|
1999-10-29 |
2001-05-03 |
Novartis Vaccines And Diagnostics S.R.L. |
Neisserial antigenic peptides
|
ES2311016T3
(es)
|
2000-01-10 |
2009-02-01 |
Novartis Vaccines And Diagnostics, Inc. |
Genes expresados diferencialmente en cancer de mama.
|
EP2275129A3
(en)
|
2000-01-17 |
2013-11-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
|
US6689599B1
(en)
|
2000-10-20 |
2004-02-10 |
Genetics Institute, Llc |
Aggrecanase molecules
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
TWI329129B
(en)
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
NZ530045A
(en)
|
2001-06-01 |
2007-07-27 |
Wyeth Corp |
Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
|
TWI267378B
(en)
|
2001-06-08 |
2006-12-01 |
Wyeth Corp |
Calcium phosphate delivery vehicles for osteoinductive proteins
|
AU2002319703A1
(en)
|
2001-07-27 |
2003-02-17 |
Wyeth |
Aggrecanase molecules
|
JP4413617B2
(ja)
|
2001-12-12 |
2010-02-10 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Chlamydiatrachomatisに対する免疫化
|
EP1456223B1
(en)
|
2001-12-19 |
2009-08-12 |
The University Of Chicago |
Rapidly maturing fluorescent proteins and methods for using the same
|
US7078217B2
(en)
|
2002-01-31 |
2006-07-18 |
Wyeth |
Aggrecanase molecules
|
EP1472364A4
(en)
|
2002-02-05 |
2005-12-28 |
Wyeth Corp |
TRUNK AGGRECANASE MOLECULES
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
WO2003099848A2
(en)
|
2002-05-24 |
2003-12-04 |
Restoragen Inc. |
Method for universal enzymatic production of bioactive peptides
|
WO2003099854A2
(en)
|
2002-05-24 |
2003-12-04 |
Nps Allelix Corp. |
Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
|
WO2004046177A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1675608B1
(en)
|
2003-09-12 |
2007-03-21 |
Wyeth |
Injectable calcium phosphate solid rods for delivery of osteogenic proteins
|
US7829307B2
(en)
|
2003-11-21 |
2010-11-09 |
Nps Pharmaceuticals, Inc. |
Production of glucagon-like peptide 2
|
KR20060130182A
(ko)
|
2004-02-02 |
2006-12-18 |
암브룩스, 인코포레이티드 |
변형된 인간 인터페론 폴리펩티드 및 이의 용도
|
ES2407465T3
(es)
|
2004-03-29 |
2013-06-12 |
Galpharma Co., Ltd. |
Nueva proteína galectina 9 modificada y uso de la misma
|
US7250298B2
(en)
|
2004-04-07 |
2007-07-31 |
The University Of Chicago |
Monomeric red fluorescent proteins
|
JP2008503217A
(ja)
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
WO2006091231A2
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
CA3005835C
(en)
|
2004-12-22 |
2023-01-31 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
MX2007007580A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Hormona del crecimiento humana modificada.
|
BRPI0609695A2
(pt)
|
2005-03-21 |
2011-10-18 |
Applera Corp |
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença e uma paciente sofrendo uma terapia
|
AU2006247591B2
(en)
|
2005-05-12 |
2011-12-15 |
Zymogenetics, Inc. |
Compositions and methods for modulating immune responses
|
US7749704B2
(en)
|
2005-11-01 |
2010-07-06 |
Mayo Foundation For Medical Education And Research |
Promoter polymorphisms of the BLyS gene and use in diagnostic methods
|
DK2339014T3
(en)
|
2005-11-16 |
2015-07-20 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
CA2663083A1
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
DK2068909T3
(da)
|
2007-03-30 |
2012-08-06 |
Ambrx Inc |
Modificerede FGF-21-polypeptider og anvendelse heraf
|
WO2009046407A2
(en)
|
2007-10-04 |
2009-04-09 |
Zymogenetics, Inc. |
B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
|
WO2009059305A2
(en)
|
2007-11-01 |
2009-05-07 |
The University Of Chicago |
Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
|
MX338336B
(es)
|
2007-11-20 |
2016-04-07 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
WO2009073511A2
(en)
|
2007-11-30 |
2009-06-11 |
Mayo Foundation For Medical Education And Research |
Polymorphisms of the blys gene and use in diagnostic methods
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
PL3225248T3
(pl)
|
2008-07-23 |
2023-11-27 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
|
CA2737026C
(en)
|
2008-09-26 |
2019-12-24 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
AU2009296267B2
(en)
|
2008-09-26 |
2013-10-31 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
EP2292781A1
(en)
|
2009-08-17 |
2011-03-09 |
Genethon |
Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
|
EP2333074A1
(en)
|
2009-12-14 |
2011-06-15 |
Robert Steinfeld |
Substances and methods for the treatment of lysosmal storage diseases
|
BR112012015597A2
(pt)
|
2009-12-21 |
2017-01-31 |
Ambrx Inc |
peptídeos de somatotropina suínos modificados e seus usos
|
EP2516454A4
(en)
|
2009-12-21 |
2013-05-22 |
Ambrx Inc |
MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND ITS USES
|
NZ607069A
(en)
|
2010-08-17 |
2014-10-31 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
ES2623780T3
(es)
|
2011-07-27 |
2017-07-12 |
Genethon |
Sistemas de expresión de baculovirus mejorados
|
CN112538501A
(zh)
|
2013-09-12 |
2021-03-23 |
生物马林药物股份有限公司 |
腺相关病毒因子viii载体
|
WO2016065326A2
(en)
|
2014-10-24 |
2016-04-28 |
Bristol-Myers Squibb Company |
Modified fgf-21 polypeptides and uses thereof
|
TWI756185B
(zh)
|
2015-09-24 |
2022-03-01 |
美商拜奧馬林製藥公司 |
腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
|
ES3034857T3
(en)
|
2015-11-12 |
2025-08-25 |
The Res Institute At Nationwide Childrens Hospital |
Methods of treating muscular dystrophy
|
EP3491008A2
(en)
|
2016-07-26 |
2019-06-05 |
BioMarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
AU2018219283B2
(en)
|
2017-02-08 |
2022-05-19 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US20200231986A1
(en)
|
2017-09-29 |
2020-07-23 |
Massachusetts Eye And Ear Infirmary |
Production of adeno-associated viruses in insect cells
|
KR102824021B1
(ko)
|
2018-01-31 |
2025-06-24 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
2c형 지대근이영양증에 대한 유전자 치료
|
CN113164762A
(zh)
|
2018-05-09 |
2021-07-23 |
生物马林药物股份有限公司 |
苯丙酮尿症的治疗方法
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
SG11202010832YA
(en)
|
2018-05-14 |
2020-11-27 |
Biomarin Pharm Inc |
Stable expression of aav vectors in juvenile subjects
|
SG11202012715UA
(en)
|
2018-06-29 |
2021-01-28 |
Res Inst Nationwide Childrens Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
AU2020229340A1
(en)
|
2019-02-26 |
2021-09-16 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy
|
US20200362368A1
(en)
|
2019-05-14 |
2020-11-19 |
Biomarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
CN114945583B
(zh)
|
2019-08-21 |
2025-04-29 |
全国儿童医院研究所 |
Α-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗
|
EP4034642A1
(en)
|
2019-09-27 |
2022-08-03 |
BioMarin Pharmaceutical Inc. |
Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies
|
BR112022009279A2
(pt)
|
2019-11-14 |
2022-09-06 |
Biomarin Pharm Inc |
Tratamento de angioedema hereditário com vetores de terapia gênica específicos do fígado
|
WO2021163079A1
(en)
|
2020-02-10 |
2021-08-19 |
Biomarin Pharmaceutical Inc. |
Virus-free cell cultures
|
WO2021183895A1
(en)
|
2020-03-13 |
2021-09-16 |
Biomarin Pharmaceutical Inc. |
Treatment of fabry disease with aav gene therapy vectors
|
TW202144575A
(zh)
|
2020-04-03 |
2021-12-01 |
美商拜奧馬林製藥公司 |
使用aav及治療調配物之苯酮尿症治療
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
WO2022094461A1
(en)
|
2020-11-02 |
2022-05-05 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
WO2023056436A2
(en)
|
2021-10-01 |
2023-04-06 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
|
EP4219726A1
(en)
|
2021-10-15 |
2023-08-02 |
Research Institute at Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
EP4590839A1
(en)
|
2022-09-22 |
2025-07-30 |
Dinaqor AG |
Treatment of cardiomyopathy with aav gene therapy vectors
|
TW202444398A
(zh)
|
2023-01-09 |
2024-11-16 |
美商拜奧馬林製藥公司 |
表觀遺傳修飾劑改善aav基因療法之耐久性
|
WO2024238591A2
(en)
|
2023-05-15 |
2024-11-21 |
Biomarin Pharmaceutical Inc. |
Methods of treating anti-aav seropositive hemophilia patients
|